We are live on ! Find out more
SM

Sabby Management Portfolio holdings

AUM $45.1M
1-Year Est. Return 74.25%
This Fund
S&P 500
This Quarter Est. Return
-3.5%
1 Year Est. Return
-74.25%
3 Year Est. Return
-95.86%
5 Year Est. Return
-99.36%
10 Year Est. Return
-99.46%
AUM
$1.82B
AUM Growth
-$609M
Cap. Flow
-$347M
Cap. Flow %
-19.1%
Top 10 Hldgs %
52.59%
Holding
435
New
56
Increased
93
Reduced
114
Closed
122

Top Buys

Rank Stock Value
1
ALKS icon
Alkermes
ALKS
+$9.22M
2
TBRA
Tobira Therapeutics, Inc. Common Stock
TBRA
+$7.3M
3
GWPH
GW Pharmaceuticals Plc American Depositary Shares
GWPH
+$7.22M
4
UTHR icon
United Therapeutics
UTHR
+$5.06M
5
LUMO
Lumos Pharma, Inc. Common Stock
LUMO
+$4.98M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$22.6M
2
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$18.2M
3
VTRS icon
Viatris
VTRS
+$18.1M
4
PXD
Pioneer Natural Resource Co.
PXD
+$15M
5
EW icon
Edwards Lifesciences
EW
+$11.6M

Sector Composition

Rank Sector Weight
1 Healthcare 10.47%
2 Technology 0.45%
3 Consumer Staples 0.1%
4 Industrials 0.09%
5 Materials 0.03%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AAPL icon
26
CALL
Apple
AAPL
$5.01T
$11.7M 0.64%
4,440
– –
BMY icon
27
CALL
Bristol-Myers Squibb
BMY
$130B
$11.3M 0.62%
1,649
-1,424
-46% -$94.1K
GWPH
28
DELISTED
GW Pharmaceuticals Plc American Depositary Shares
GWPH
$11.1M 0.61%
160,406
+88,649
+124% +$7.22M
SRPT icon
29
CALL
Sarepta Therapeutics
SRPT
$1.65B
$11M 0.61%
2,862
-3,809
-57% -$124K
ALKS icon
30
Alkermes
ALKS
$8.1B
$10.5M 0.57%
+131,671
New +$9.22M
RGLS
31
CALL
DELISTED
Regulus Therapeutics
RGLS
$10.4M 0.57%
100
-1
-1% -$1K
EW icon
32
PUT
Edwards Lifesciences
EW
$49.3B
$9.48M 0.52%
3,600
-6,492
-64% -$169K
GILD icon
33
PUT
Gilead Sciences
GILD
$166B
$9.25M 0.51%
914
-4,059
-82% -$422K
TENX icon
34
Tenax Therapeutics
TENX
$397M
$8.84M 0.49%
84
+3
+4% +$311K
MBLY
35
PUT
DELISTED
Mobileye N.V.
MBLY
$8.5M 0.47%
2,011
-3,147
-61% -$141K
LUMO
36
CALL
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$8.12M 0.45%
248
-163
-40% -$53.1K
BPMC
37
CALL
DELISTED
Blueprint Medicines
BPMC
$7.9M 0.43%
+3,000
New +$67.5K
TBRA
38
DELISTED
Tobira Therapeutics, Inc. Common Stock
TBRA
$7.79M 0.43%
877,342
+702,399
+402% +$7.3M
MBLY
39
DELISTED
Mobileye N.V.
MBLY
$7.26M 0.4%
171,672
-64,147
-27% -$2.87M
NBIX icon
40
CALL
Neurocrine Biosciences
NBIX
$18.2B
$7.22M 0.4%
1,277
-126
-9% -$6.4K
ASRT
41
CALL
DELISTED
Assertio
ASRT
$7.2M 0.4%
66
+21
+47% +$23.6K
IONS icon
42
CALL
Ionis Pharmaceuticals
IONS
$9.11B
$7.18M 0.39%
1,159
– –
CLDX icon
43
CALL
Celldex Therapeutics
CLDX
$2.84B
$7.01M 0.39%
298
+1
+0.3% +$218
HALO icon
44
CALL
Halozyme
HALO
$9.84B
$6.96M 0.38%
4,014
– –
ENDP
45
CALL
DELISTED
Endo International plc
ENDP
$6.58M 0.36%
1,075
+474
+79% +$28.8K
BMRN icon
46
BioMarin Pharmaceuticals
BMRN
$12B
– –
-174,073
Closed -$18.2M
GBT
47
DELISTED
Global Blood Therapeutics, Inc.
GBT
$6.45M 0.35%
342,857
– –
ACHN
48
CALL
DELISTED
Achillion Pharmaceuticals
ACHN
$6.34M 0.35%
5,878
-1,038
-15% -$9.44K
LUMO
49
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
$6.23M 0.34%
19,030
+15,290
+409% +$4.98M
TXMD icon
50
CALL
TherapeuticsMD
TXMD
$23.7M
$6.22M 0.34%
120
-76
-39% -$28.1K
1
2
3 4 5

Similar funds

CG
Circumference Group Little Rock, Arkansas $44.6M AUM 5.21% 1-Year Est. Return
OC
Optimas Capital Central, Hong Kong $44.5M AUM 24.43% 1-Year Est. Return
ICCON
Investment Counsel Company of Nevada Las Vegas, Nevada $44.5M AUM 21.97% 1-Year Est. Return
PCM
Prentice Capital Management Greenwich, Connecticut $45.7M AUM 2.65% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $46.3M AUM 48.82% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
CTC
Corundum Trust Company Sioux Falls, South Dakota $43.8M AUM 20.07% 1-Year Est. Return

Sabby Management's Q4 2015 Portfolio in Review

As of Q4 2015, Sabby Management held 435 positions worth $1.82B, down 25% from $2.43B the previous quarter. Its ten largest holdings account for 53% of the portfolio.

Sabby Management withdrew a net $347M in Q4 2015, closing 122 positions and reducing 114 holdings. Its most notable exit was Biogen, an estimated $22.6M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 10% of assets, down from 13% a quarter earlier, followed by Technology and Consumer Staples.

Against the trend, Sabby Management opened a new position in Alkermes worth $10.5M.

  • Sabby Management's largest Q4 2015 buy was Alkermes: 131,671 shares worth $10.5M.
  • Sabby Management added most to Tobira Therapeutics, Inc. Common Stock in Q4 2015, an estimated $7.3M increase.
  • Sabby Management's biggest Q4 2015 reduction was Edwards Lifesciences, cutting an estimated $11.6M.
  • Sabby Management fully exited Biogen in Q4 2015, selling an estimated $22.6M.
  • Sabby Management's ten largest holdings make up 53% of its $1.82B portfolio in Q4 2015.
  • Sabby Management opened 56 new positions and closed 122 in Q4 2015.
  • Sabby Management's portfolio value fell 25% quarter-over-quarter to $1.82B.

Based on Sabby Management's 13F filing for Q4 2015, filed 16 Feb 2016.